The League Aims

The European and Mediterranean League against Thrombotic Diseases (EMLTD) is a multidisciplinary non-profit Scientific Society with a great tradition, created more than 40 years ago with the aim to promote the scientific advance and dissemination of knowledge in the diagnosis, prophylaxis and treatment of Thrombosis and Haemostasis.

The Society aims to create bridges between the clinical practice and the basic science, bringing together research scientists on vascular and molecular biology and clinicians of many different specialties related to thrombosis (hematology, cardiology, neurology, internal medicine, gynecology, pharmacy, biochemistry and other disciplines).

The EMLTD contributes to the translation of scientific advances to the clinical practice with a multidisciplinary and international approach organizing international Congresses on thrombosis, educational courses and symposia oriented to the advance in the fight against thrombosis.

The League Bylaw

NAME. OBJECTIVES. TERRITORIAL AREA. DOMICILE

Article 1. Name and objectives

The European and Mediterranean League against Thrombotic Diseases (hereafter called The EMLTD) is organized to scientific and educational purposes and has as its objectives and aims to promote the study of the origin and causes of thromboembolic diseases as well as their diagnosis, prophylaxis and treatment and to gather professionals interested in thrombosis and Hemostasis from the basic to clinical sciences

Article 2. Territorial Area

The territorial areas for the scientific activities of the EMLTD are the European and Mediterranean countries and will be ruled by Spanish Law of Associations of March 22, 1/ 2002 and by the present bylaws.

Article 3. Activities

To achieve the above mentioned objectives, EMLTD's members will promote clinical research studies on patients with thromboembolic diseases, will participate ordinarily in this research and will foster exchange and diffusion, with all EMLTD’s members, regarding achievements obtained either individually or in teams in order to establish Thrombosis:
a) etiopathogenesis
b) diagnosis
c) treatmen
t d) epidemiology
e) genetics
f) nutrition in order to achieve patients full
incorporation into their previous normal activities. For this purpose The EMLTD will periodically organize in adequate places, and in accordance with the current approved rules of the EMLTD, Congresses, Educational Courses and Conferences, Seminars, Symposia, Publications and any other event towards achieving its objectives.

Article 4. Domicile

Social domicile of The EMLTD will be located in Pabellón Docente UPV ¬Escuela de Enfermería, Hospital de Basurto, C/ Gurtubay s/n, 48013. Bilbao. Spain

CHAPTER II: MEMBERS: CLASSES, ADMISSION PROCEDURE, RIGHTS AND OBLIGATIONS

Article 5. Member classes.

The EMLTD will have the following types of membership: Ordinary, Honorary and Sponsoring Members.

Article 6. Admission procedure

  • a) Ordinary members. Professionals willing to become members of The EMLTD from all over the world, must present their written application by mail or through the EMLTD Web to the Technical Secretariat. A brief CV may be asked to The Secretariat will submit the application to the Executive Board for their approval or disapproval. General Assembly will be reported of the admitted members and has the decisive right in case of claims for not being admitted.
  • b) Sponsoring members. Firms and Institutions interested in the EMLTD's objectives can be admitted into this class. The Executive Board will receive admission for each application and acceptance will be by simple majority of votes by the Council of the EMLTD.
  • c)Honorary members. They could be those EMLTD members amongst the EMLTD Founders and distinguished professionals that in the past gave their scientific contributions to the EMLTD as former Councilors. New inclusions could be proposed by 10 EMLTD members and approved by the managing EMLTD organs.

Article 7. Ordinary members rights

All Ordinary members will have identical rights.
a) To vote and to be eligible for any job within the Council and Executive Boards.
b) To have voice and vote in all deliberations and agreements taken at the General Assembly.
c) To examine accounts and social documents within the agreed times, established by the Executive Board.
d) To present, by means of written proposals to the Executive Board, as many projects, ideas or initiatives as deemed useful or necessary for the best development of the EMLTD. e) To use all services available within the Society as well as to participate in all activities necessary for the aims of the EMLTD.

Article 8. Ordinary members obligations

All Ordinary members will have identical obligations:
a) To attend, whenever called for, to the General Assembly or before the Executive Board, under its requirement, to deal fixed and singular business
b) To fulfill the present bylaws and all agreements made by the Executive Board and the General Assembly.
c) To execute with the greatest zeal and enthusiasm all actions requested by the Executive Board in relation to the EMLTD's aims.
d) To accept and develop, when duly elected, Managing appointments except for serious reasons so deemed by the Executive Board.
e) To pay in time annual dues established by the General Assembly under proposal by the Executive Board.

Article 9. Membership loss

Ordinary membership may be lost:
a) By request of the member himself by means of written application addressed to the Executive Board.
b) By not paying ordinary annual dues for at least two years, except for a justified reason.
c) By agreement of the Executive Board, after listening to the member, when its social or professional behavior is worth of such expulsion. In this case, Executive Board agreement my be claimed before the General Assembly, that will decide with irrevocable right in an extraordinary meeting convoked to this effect, In any case, the resignation or expulsion of the Member is always the only competence of the General Assembly, and requires always its ratification when the Executive Board has agreed the expulsion as it is established under c) of this article.

Article 10. Honorary members rights

The honorary members can participate in the EMLTD General Assembly with voice but not with vote, participate in the EMLTD scientific activities and use all services available within the Society. Honorary members will be excluded of the annual dues of ordinary membership.

Article 11. Sponsoring members

Sponsoring members will have those rights and obligations assumed on their incorporation. Election and continuity of these Sponsoring Members will be based on their financial contributions to The EMLTD, suggested by the Executive Board and approved at the EMLTD's Council. Consequently their membership will be lost by the failure to respect their assumed obligations. Sponsoring Members will enjoy priority rights in EMLTD's International Thrombosis Congresses and in organising Satellite Symposia.

CHAPTER III: ECONOMICAL REGIME

Article 12. EMLTD’s finances

The EMLTD income or financial means come from: a) Ordinary members annual dues.
b) Sponsoring Members annual dues.
c) The surplus of the ITC congress or other scientific activities according to the current rules accepted by the Council and General assembly.
d) Grants or donations to the EMLTD by Public or Private Institutions, from any country in the world, which will be written down by the Council/Executive Board in the minutes made on occasion of the first periodical meeting.
e) Mobile or immobile property of any kind that may correspond to the EMLTD by inheritance or legacy or any other lucrative title, with the mandatory acceptance by the Council/Executive Board.

Article 13. Yearly Budget and Administration

EMLTD's financial funds will be administered by the Executive Board that will determine adequate Register Books for accountancy, according to actual laws in this matter.

CHAPTER IV: EMLTD ASSOCIATED COUNTRIES

Article 14.

The EMLTD will consider the association of a new country after an official letter of intend of at least 6 EMLTD members in that country, who are in agreement with the aims of the EMLTD and accept the current Bylaws and the Regulations of the Society. The letter of intend should include the CV of the solicitants and a proposal of one of them as the country representative as a Councilor and another for the Scientific Board representing that country. Proposals will be consider by the Executive Board in representation of the Council, and discussed in the Board’s Meeting. Final decision will be at the General Assembly of the Society.

CHAPTER V: EMLTD'S MANAGING AND FUNCTIONING ORGANS

Article 15.

EMLTD's managing and functioning organs are: Council Board, Executive Board, Scientific Board and Educational board. The managing organs may establish other Boards or Committees as it shall deem necessary.

Article 16. Council

Council will have as main function to promote and enhance EMLTDs activities in their respective countries, encouraging new members registration and other countries into the EMLTD. EMLTD’s Council will be composed by up to two ordinary members in good standing of the founding countries, except Spain which will have two representatives and the General Secretary in the council. Non- founder countries will have one representative in the Council. Councilors will be proposed either by the EMLTD members in that country by democratic voting if number of EMLTD members are more of 6, otherwise, may be proposed by the EMLTD’s managing and functioning organs amongst people of renown scientific level in Thrombosis and Hemostasis within the country willing to associate with the EMLTD. Acceptance of new Councilors will be by the General Assembly. The councilors will stay four years with only one renovation possible. The EMLTD Council will have as President, during two years the President of the International Thrombosis Congress as from the closing Ceremony of the Congress organized. Council's members will meet at least once every two years during the Thrombosis Congress to deal about EMLTD's new important matters, under Presidents convocation.

Article 17. Council Functions.

a) President will represent the Society in all its external relations with the Public Powers, Institutions, Corporations and any kind of physical persons, as well as in all actions, contacts in which The EMLTD may be involved, and in all kinds of matters or administrative and judicial business, for which he may grant opportune legal proxy powers.
b) To decide on Ordinary Members admission or dismissal as established under article 9.
c) To convoke General Assemblies as it is established in these Bylaws and to execute valid agreements reached in the General Assembly.
d) Raise founds so that the EMLTD might be able to execute its aims and be informed by the treasurer about the finances.
e) Councilors or members of the EMLTD Boards can bid for the organization every second year the EMLTDs International Thrombosis Congress.

Article 18. General Permanent Secretariat

The Council will also have a General Permanent Secretariat, whose Secretary as a EMLTD’s Councilor, since the EMLTDs foundation, will be a Spanish Ordinary member elected by the Council. The term of service of the General Secretariat is a period of four years, which can be extended by further periods of four years with the agreement of the EMLTD Council and General Assembly. His main function will be to coordinate Councilors activities and enhance EMLTDs development within the associated countries. To develop this task, the General Secretary-Treasurer will be provided with the opportune legal proxy powers and financial means, with the obligation to inform periodically to the EMLTDs Managing and Functioning Organs.

Article 19. Executive Board

The Society will be managed and administered by an Executive Board of seven (7) members that will act as the executive branch of the Council. The Executive Board will be constituted by the President of the EMLTD, the former President, a General Secretary-Treasurer and four (4) other members elected among EMLTD members of the Council and/or the EMLTD Boards in good standing. The new President can, at his election, renew two members of the Executive Board and to replace them with other two members among members of the Council and/or the EMLTD Boards.

The Executive Board will be in activity for a period of two years (the two following years after the Congress of the EMLTD.).

Article 20. Executive Board Functions

Executive Board will meet at least once a year. They will meet also when requested by the President under his initiative.
Its functions will be:
a) To establish EMLTD's yearly budget and show its yearly accountancy and financial balance.
b) To be responsible for the whole administrative work of the EMLTD.
c) To nominate an Assistant or Manager.
d) To keep adequate relations, through the Associated Editor, with the Official Journal of the EMLTD.
e) To enforce fulfillment of all members’ rights and obligations and, in particular, execution of financial regime as per articles 12 and 13 of present bylaws.

Article 21. Agreements

Executive Board will undertake agreements by majority being Chairman's vote decisive in case of a tied voting. In order that agreements might be obligatory, the presence of at least two thirds of Executive Board members is necessary.

Article 22. Educational Board

Educational Board. Ensures the greatest possible impact of the Society’s educational programs on the thrombosis and hemostasis clinical and scientific community. The Educational Board will have a president and the appropriate number of members up to 10. Members will be proposed by the Council and approved by the General Assembly. The term will be four years which could be extended to another period of four years.

Article 23. International Scientific Committee

Will be composed of professionals of international scientific prestige, who under the council’s proposal, will be approved at the General Assembly. Its function will be to collaborate in the EMLTD scientific and educational activities and to collaborate and reinforce Councilors tasks. The term will be 4 years, which could be extended for another period of 4 years

CHAPTER VI: FUNCTIONS OF EXECUTIVE BOARD OFFICERS

Article 24. President

It is the right of the Executive Board's President:
a) To convoke and preside meetings of the Executive Board, determining himself the meeting's agenda.
b)To order necessary payments to satisfy EMLTD's needs according to expenses budget.
c) To convoke and preside meetings of the Executive Board, determining himself the meeting's agenda.
d) To authorize with his signature as many documents as required for administrating the EMLTD; for some of these functions he will grant opportune legal proxy powers.
e) To undertake by himself, in urgency cases, opportune decisions submitting them for approval by the Executive Board at the first available meeting of the Board.

Article 25. Vice-¬President (former President of the EMLTD)

It is the right of the Vice-President to substitute the President in his absence and to hold Executive Board Chairmanship whenever it is vacant. He may have all functions and faculties, which the President might delegate to him.

Article 26. Treasurer (Secretary General)

The Treasurer will be in charge to rise and to keep EMLTD's funds, accountancy, and payment of bills for the normal functioning of the EMLTD, which will be reported and approved by the Executive Board. He will present the income and expenses yearly budget, which after being approved by the Executive Board, must be positively voted by the General Assembly.

Article 27. Vocals

They will help all Executive Officers, when necessary, in their functions and administrative work.

CHAPTER VII: GENERAL ASSEMBLY

Article 28. Functions

General Assembly is the EMLTD's supreme organ and its agreements are mandatory to all EMLTD's members, who, being in good standing order, are entitled to attend to its meetings either personally or duly represented.

Article 29. Classes

General Assembly can be ordinary or extraordinary. Ordinary Members, who are in good standing order, have the right to attend to them with voice and vote. Sponsoring members, who are in good standing order, may attend only as listeners but without voice and vote.

Article 30. Convocation

General Assembly, both ordinary and extraordinary, will be convoked by the Council's President under his initiative or under a request of twenty members, by written application in which affairs to be dealt with must be clearly specified, and will take place, at least, every second year, within the celebration of the International Thrombosis Congress.

Article 31. Convocation procedure

General Assembly convocation must comprise agenda matters, place and site, date and hour for the meeting to be held. General Assembly, both ordinary and extraordinary, will be validly constituted, on first call, when attended by majority of members, present or duly represented, and, on second call, whatever number of members is present. Between the convocation date and the General Assembly meeting, there must be a period of fifteen days. Second call for the meeting can be made on same convocation but with a half hour delay to start the meeting after the hour of the first call. lf the second call has not been foreseen in the convocation announcement, then a period of at least eight days is required. The President will sign the convocation and he will send it to members by Email or postal service.

Article 32. Agreements

General Assembly, both ordinary and extraordinary, agreements should be adopted by majority of votes. In the case of a tied voting, President will decide with his quality vote. These agreements will be valid and, consequently, executive and mandatory for all members, whatever the number of attendants.

Article 33. Voting

Voting can be ordinary, nominal or secret. Nominal voting will be held at the request of half of the members attending to the meeting. Secret voting will be held when affairs which are dealt concern to some member’s dignity and decor. General Assembly can also undertake agreements by unanimous general approval.

Article 34. Discussions

General Assembly will be presided and ruled by the President or his substitute amongst the Councilors. He will give members faculty to talk when applied for and will take away this talking faculty from members due to incorrect behavior or speaking on matters out of agenda affair or too long explanations or discussions. The General Assembly will approve or discuss the decisions of the Council.

Article 35. Ordinary General Assembly

Ordinary General Assembly will be held once every second year during the celebration of EMLTD's International Congress on Thrombosis and shall deal on the following matters: a) Reading and approval of previous minutes. b) Reading and approval of Activities Memory, undertaken by the EMLTD in the preceding two years. c) Revision and approval of accountancy of income and expenses of preceding two years. d) Revision and approval of the budget of income and expenses for the next two present years. e) Storming and discussion of scientific matters in the EMLTD's fields when the members consider them interesting in view of the undertaken research. f) Special matters g) Requests and questions.

Article 36. Extraordinary agreements

General Assembly, both ordinary and extraordinary, will not be entitled to deliberate or decide on matters, which are not written down in the Convocation Agenda. It is clearly established that the favorable vote of two thirds of present, or duly represented, members will be necessary in an Extraordinary Assembly to dispose or give up the goods of the EMLTD, modification of Bylaws, dissolution of the EMLTD, as well as to assume big amounts credit obligations or loans.

Article 37. Minutes

Minutes will be written on all meetings held, signed by the General Secretary with the Placet of the President/Chairman and they will be registered in the corresponding minute archive.

CHAPTER VIII:DISSOLUTION OF THE EMLTD

Article 38. Dissolution

The EMLTD shall be dissolved by agreement of the Extraordinary General Assembly, duly convoked by the EMLTD's President to this effect with an extraordinary call in whose day’s agenda Society dissolution will be the only matter to be dealt with. It can also be dissolved by causes determined in article 39 of Spanish Civil Law and by Judge's sentence.

Article 39. Liquidation

Executive Board, increased with three of most ancient members, will be in charge to carry out liquidation of Society, after having been constituted as such as a Commission of liquidation; it will proceed to require due quantities to be cashed and to see all its actual assets at that moment, and to distribute or derive final product obtained to entities or foundations with beneficence character, esteemed as such by them with full right to execute it.

Additional disposition

All matters, which are not defined in these BY¬LAWS, shall be dealt according to the actual Spanish Law of Associations and any other laws, which may substitute or supplement it.

EMLTD Boards

COUNCILORS BOARD

President

  • A. M. Demir (Turkey)
  • General Secretary

  • T. Padró (Spain)

  • COUNTRY COUNCILORS

  • I. B. Topalov (Bulgaria)
  • A. Bronic (Croatia)
  • A. Nicolaides (Cyprus)
  • N. Kassim (Egypt)
  • J.F. Schved (France)
  • I. Elalamy (France)
  • A. Hatzizacharias (Greece)
  • U. Seligsohn (Israel)
  • D. Varon (Israel)
  • M. B. Donati (Italy)
  • P. Prandoni (Italy)
  • A. Taher (Lebanon)
  • C. Abdelkhirane (Morocco)
  • Z. Tazi (Morocco)
  • E. V. Roitman (Russia)
  • A.K. Al Momen (Saudi Arabia)
  • I. Elezovic (Serbia)
  • M. Kozak (Slovenia)
  • T. Padró (Spain)
  • M. T. Santos (Spain)
  • L. Badimon (Spain)
  • S. Guermazi (Tunisia)
  • T. Ulutin (Turkey)
  • A. Tselepis (Greece)
  • A. M. Demir (Turkey)
  • J. Morais (Portugal).

  • EXECUTIVE BOARD

    President

  • A. M. Demir (Turkey)
  • Past President

  • L. Badimon (Spain)
  • General Secretary

  • T. Padró (Spain)
  • Members

  • I. Elalamy (France)
  • P. Prandoni (Italy)
  • D. Varon (Israel)
  • M.T. Santos (Spain)

  • EDUCATIONAL BOARD

    President

  • S. Coccheri (Italy)
  • Members

  • L. Badimon (Spain)
  • P. Balas (Greece)
  • M. B. Donati (Italy)
  • I. Elalamy (France)
  • A. Gialeraki (Greece)
  • J. Monasterio (Spain)
  • M.T. Santos (Spain)
  • M. Stegnar (Slovenia)

  • INTERNATIONAL SCIENTIFIC COMMITTEE

  • M. Bozic-Mijovski (Slovenia)
  • B. Brenner (Israel)
  • M. Brochier (France)
  • R. Bernat (Croatia)
  • M. Cattaneo (Italy)
  • M. Demir (Turkey)
  • G. Gerotziafas (France)
  • A. Gialeraki (Greece)
  • H. A. Goubran (Egypt)
  • Z. Jerbi (Tunis)
  • I. M. Khalil (Lebanon)
  • G. Kenet (Israel)
  • I. Kontopoulou (Greece)
  • M. Stegnar (Slovenia)
  • A. M. Lucic (Yugoslavia)
  • M. Monreal (Spain)
  • G. Palareti (Italy)
  • J. A. Paramo (Spain)
  • D. Radak (Serbia)
  • T. Sipah (Turkey)
  • F. Uras (Turkey)
  • M. Vacas (Spain)
  • J. Vallés (Spain)
  • A. M. Demir (Turkey)
  • M.C. Ar (Turkey)
  • A. Unuvar (Turkey)

  • HONORARY MEMBERS

  • J. Aznar Lucea (Spain)
  • P. Balas (Greece)
  • S. Coccheri (Italy)
  • J. A. Iriarte (Spain) (*)
  • S. Levy-Toledano (France)
  • T. Mandalaki (Greece)
  • J. Monasterio (Spain)
  • M Samama (France) (*)
  • O. N. Ulutin (Turkey) (*)
  • C. A. Villaverde (Spain)


  • * Passed away

    EMLTD History

    The League History

    Past, present and future and relations with ISTH

  • by Jasone Monasterio
  • In the 1960's, Thrombosis even though an important cause of mortality and morbidity, was not yet recognised as an important medical problem, and progressive efforts were needed for it to be accepted as a specific medical entity requiring clinical studies and research.

    In the clinical practise, thrombosis occurred always as a complication causing vascular obstruction, infarction or necrosis; nevertheless morbidity or mortality was attributed clinically to the failure of some particular organ systems such as the heart, lungs or brain, but not to the originating thrombosis.

    A similar situation existed in the field of research. There was not much interdisciplinary study, communication or multidisciplinary approach among scientists in thrombosis.

    They were more concerned with elucidating which defects were underlying haemorrhagic problems rather than the factors and mechanisms responsible for thrombosis, which were much more unknown and complex.

    During this decade, in the world there were no International Scientific Societies in Thrombosis except the Task Force on Thrombosis in 1965 promoted by Sol Sherry and JM Stengle, who also were responsible for the International Committee of Haemostasis and Thrombosis with annual meetings.

    Within this atmosphere, and after four years of clinical stage at the National Blood Transfusion Centre with Prof JP Soulier, in Paris, and in University Public Hospitals with leading experts in Haematology and Haemostasis ( Dr. Samama, Dr.Leroux, Dr Josso..), I returned to Bilbao and with the initiative and support of Dr JA. Iriarte from the Institute of Procardíacos ( devoted to heart illnesses), we attracted the attention of Dr M.M.Samama to organise the First HISPANO-FRANCES Symponium on " Haemorrhagic Syndromes and Thromboembolic Diseases", in Bilbao in 1967, in order to get in contact with French and Spanish leaders in Haemostasia, Angiology, Cardiology and other disciplines, who would be interested in Thrombosis.

    Amongst the speakers were Drs. Babío, Balaguer, Calderón, Castillo, Ezcurra, Iriarte JA, Iriarte M, Landa, Monasterio, Raichs and Rey Baltar from Spain and Drs.Bodineau, Bondil, Bordes, Goglin, Leroux, Samama, Raby, Vairel, Veber and Yver from France.

    In the Symposium book, published in Spanish in 1967, there were papers on the following topics, demonstrating our interest for thrombosis:

  • - Double aspects of hypercoagulability.
  • - Hypercoagulability as biological and clinical syndrome
  • - Hypercoagulability as potential cause of the venous fibrin thrombus
  • - Risk factors in the myocardial infarct and its social consequences.
  • - Other Haemostasis alterations in diabetes beside haemorrhages and their relations with pathogenetic mechanisms.
  • - Control of anticoagulant therapy through thromboelastography
  • - Abdominal vascular occlusions - Subcutaneous prophylactic heparin as advanced therapeutics
  • - Distal members arterial embolism treated with streptokinase in 67 patients from 1961 (Prof. Samama).
  • - Fibrinolysis diagnostics especially in hyperfibrinolysis states
  • At the end of this First Hispano-Francés Symposium , there was an agreement to hold another meeting in two years time inviting leaders from Italy ( as Prof. De Nicola) and from other Mediterranean Countries (Prof De Vries, Ulutin, Mandalaki….).

    As well at the end of this First Spanish and French Symposium it was established a protocol for the diagnosis and treatment of Thromboembolism.

    This First Spanish and French Symposium was the seed from which the Mediterranean League against Thromboembolic Diseases (MLTD) originated. Enclosed you will find the agreement made and published in Spanish in the SYMPOSIUM BOOK.

    At the end of the 1960's, scientists and clinicians started to recognise thrombosis as an specific entity associated with many pathologies such as atherosclerosis and traumatisms and to risk factors which modify vessels wall, blood components and blood flow, that undertake a different participation in the genesis of arterial and venous thrombosis.

    The First Mediterranean Congress on Thromboembolism was held again in Bilbao (Spain) on 22nd-25th October, 1969. In the General Assembly held at the end of this Congress, the Mediterranean League was founded officially as seen in the enclosed document, published in the Congress Book (in Spanish Language).

    The Founding Countries and Counsellors were: Bulgaria (Dr. Anastassoff), France (Dr. Samama), Greece (Dr. Mandalaki), Israel (Dr. DeVries), Italy (Dr. de Nicola), Spain (Dr. Aznar) and Turkey (Dr. ON Ulutin). Dr. JA Iriarte was appointed as General Secretary.

    According to its Bye-Laws, The Mediterranean League against Thromboembolic Diseases (hereafter called The LEAGUE or MLTD) was founded for scientific and educational purposes and had as its objectives and aims to promote the study, the origin and causes of Thromboembolic diseases as well as their diagnosis, prophylaxis and treatment and to gather professionals interested in thrombosis and Haemostasis from the basic to clinical sciences.

    To achieve the above mentioned objectives, League's members would promote clinical research studies on patients with Thromboembolic diseases, would participate ordinarily in this research and would foster exchange and diffusion, with all League's members, regarding achievements obtained either individually or in teams in order to establish Thrombosis: a) etiopathogenesis b) diagnosis c) treatment d) epidemiology, e) genetics f) nutrition, in order to achieve the patients full incorporation into their previous normal activities. For this purpose The League would periodically organise in adequate places, in all countries of the Mediterranean area, Congresses, Educational Courses and Conferences, Seminars, Symposia, Publications and any other event towards achieving its objectives.

    The following 3 International Thrombosis Congresses were held in the founding Countries and organised by the Founding Councillors, Dr. Orhan N Ulutin in Istanbul (Turkey) in 1971, Dr. A De Vries in Tel Aviv ( Israel) in 1973 and Dr. Titika Mandalaki in Athens (Greece) in 1976. Official Languages were French and English.

    THE MEDITERRANEAN LEAGUE's INTERNATIONAL THROMBOSIS CONGRESSES

    Nº PLACE COUNTRY DATE MONTH YEAR PRESIDENT

  • I Bilbao Spain 22 - 25 October 1969 J.A. Iriarte
  • II Istanbul Turkey 11 - 14 October 1971 O.N. Ulutin
  • III Tel Aviv Israel 3 - 8 June 1973 A. de Vries
  • IV Athens Greece 2 - 6 May 1976 T. Mandalaki
  • Due to the increasing success of attendance and to the high scientific level of these meetings, the founding Councillors advised the General Secretary to register the Mediterranean League as a Scientific Society legally in Spain. It was officially registered on June 19th, 1980 with the number 36.121 in the National Register of Associations of Spain according to the Law of December 24th, 1964.

    Now-a-days, following the latest Spanish Law 1/2002, MLTD has been legally updated to this Law on February 2nd, 2007.

    During this first decade, four Countries from the three Mediterranean Continents were incorporated into the League: Egypt (with Dr. Hassanein as Councillor), in 1971, and Tunisia, Lebanon and Yugoslavia with Dr. Houissa-Kastally, Dr. Taleb, and Dr. Baklaja as their respective Councillors in 1973. Rumania with Dr. Pieptea was accepted as observer Country.

    The following decade, from V International Thrombosis Congress, (ITC) organised by Dr. Sergio Coccheri in Bologna in June 1978 until the X ITC held in Athens in 1988 under the organisation of Dr T.Mandalaki, gave the MLTD a sound and consolidated ground as an International Scientific Society in the field of Thromboembolic diseases. There were 600 attendants at the X ITC of Athens in 1988. That represented a significant jump and growth in the international success and acceptance of MLTD.

    The MLTD had to update its original Bye-laws to keep pace with the increasing number of countries and scientific activities. The new By-Laws were approved and legally registered in Spain on 27th July 1989.

    THE MEDITERRANEAN LEAGUE's INTERNATIONAL THROMBOSIS CONGRESSES

    Nº PLACE COUNTRY DATE MONTH YEAR PRESIDENT

  • V Bologna Italy 29 - 2 May - June 1978 S. Coccheri
  • VI Montecarlo France 23 - 25 October 1980 M.M. Samama

  • VII Valencia Spain 13 - 16 October 1982 J. Aznar
  • VIII Istanbul Turkey 4 - 7 June 1984 O.N. Ulutin
  • IX Jerusalen Israel 1 - 6 June 1986 U. Seligsohn
  • X Athens Greece 22 - 27 May 1988 T. Mandalaki
  • Drs M.Samama, J.Aznar, ON Ulutin , U Seligsohn and T. Mandalaki organised increasingly successful ITCs in Montecarlo ( 1980), Valencia ( 1982), Istanbul (1984), Jerusalem (1986) and Greece ( 1988) respectively.

    At the Councillors meeting held in Istambul in 1984, an agreement was reached between the MLTD and the CLAHT to interchange scientific knowledge and to invite two speakers in to their respective International Congresses. This Agreement was ratified again in Brussels in 1987.

    THE MEDITERRANEAN LEAGUE's INTERNATIONAL THROMBOSIS CONGRESSES

    Nº PLACE COUNTRY DATE MONTH YEAR PRESIDENT

  • XI Ljubljana Yugoslavia 24 - 28 June 1990 D. Keber
  • XII Firence Italy 18 - 23 May 1992 G. Neri Serneri
  • XIII Bilbao Spain 6 - 10 June 1994 J.A. Iriarte
  • XIV Montpellier France 14 - 18 October 1996 M.M. Samama
  • XV Antalya Turkey 16 - 21 October 1998 O.N. Ulutin
  • The third decade until 1998 witnesses the flourishing of the MLTD with bigger ITCs, whose registered delegates reached 1.300 attendants from about 40 countries from all over world having leading international experts in Thrombosis as speakers.

    In 1990, within the counsellors meeting held at the X ITC of Ljubljana (Yugoslavia), Dr. F. Meriane applied for a meeting to be held in Algeria. In 1992 Dr Houissa- Kastally asked the Councillors Board for a symposium to be organised in May/June 1993 in Tunisia.

    New countries were incorporated into MLTD. In 1992, Slovenia with Dr Keber as a Country Councillor and Dr M Stegnar as member of the Scientific Committee; Portugal ( with Drs. Campos and Cunya Ribeiro as Country Councillors) in 1994, and Morocco (with Dr. N. Benchemsi as Country Councillor) in 1996.

    In 1996, MLTD's By-laws were translated by Dr. M. Sánchez Moya into English after updating its management organs in collaboration with Drs Samama, Coccheri, Seligsohn, Monasterio and Iriarte.

    In 1996, at the Montpellier's ITC, under the proposal of Dr Monasterio and Dr. H. C. Hemker, as Managing Editor, Haemostasis Journal (to-day, Pathophysiology of Haemostasis and Thrombosis) was appointed the Official Journal of the MLTD with Dr Sylvian Levi-Toledano as editor on behalf of MLTD.

    THE MEDITERRANEAN LEAGUE's INTERNATIONAL THROMBOSIS CONGRESSES

  • Nº PLACE COUNTRY DATE MONTH YEAR PRESIDENT
  • XVI Porto Portugal 5 - 8 May 2000 M. Campos
  • XVII Bologna Italy 26 - 30 October 2002 S. Coccheri
  • XVIII Ljubljana Slovenia 20 - 24 June 2004 M. Stegnar
  • XIX Tel Aviv Israel 14 - 19 May 2006 D.Varon
  • XX Athens Greece 25 - 28 June 2008 C.H. Liapis
  • The fourth decade confirmed the flourishing of MLTD with the four congresses held in Porto 2000 (Dr. Campos) Bologna 2002 ( Dr. Coccheri), Ljubljana 2004 ( Dr. Stegnar) and Tel Aviv 2006 ( Dr. Varon) reaching 1.600 attendants from 47 world countries.

    At the beginning of this last decade, Dr. Monasterio was appointed MLTD's General Secretary within the Councillors Meeting of the XVII ITC held at Bologna due to her active dedication to MLTD since its foundation as founding Member. She had previously acted as General Secretary in 1994-1996, while Dr. Iriarte was President. Three Managing Boards were introduced into the Bye-Laws: Trustees Board, Executive Board and Education Board.

    In April 2004, under request of MLTD's President, Dr. S.Coccheri, Dr. M. Sanchez-Moya, created the WEB SITE. www.medleague-thrombosis.org as a modern tool for effective and global diffusion of MLTD's activities.

    Saudi Arabia (2000) and Cyprus (2004) were incorporated into MLTD with Dr. A.K. Al Momen and Dr. Nicolaides as their respective Country Councillors.

    Dr.Nicolaides was the organiser of a meeting in Cyprus where an International Consensus on Thrombophylia and Venous Thromboembolism was reached with the participation of MLTD Members (Dr. Samama, Dr. Coccheri, Dr. J. Conard and Dr. Sami Guermazi).

    Relations with International Society of Thrombosis and Haemostasis

    Relations with the International Society of Thrombosis and Haemostasis (ISTH) have always been a model of solidarity and support to the objectives and aims of MLTD.

    In 1974, Prof. Sol Sherry and Dr James Stengle, President and Secretary of the ISTH were nominated Honours Members of the Spanish Society of Haemostasis and Thrombosis (SETH). The birth of the SETH was decided by Spanish MLTD Members during the III ITC held in Tel Aviv in 1973. Dr Stengle, representing the ISTH, attended the first General Assembly of the SETH in 1974, in Barcelona, invited by Dr. J. Monasterio, offering full support to the aims of the SETH and of the Mediterranean League against Thromboembolic Diseases, founded 5 years before 1969.

    Throughout the whole life of the MLTD, the ISTH has always offered MLTD facilities to celebrate its Annual Councillors Meeting within ISTH's International Congresses, due to the friendly relation between the ISTH Authorities and Mediterranean League Councillors and Secretariat.

    ISTH's Logo appears on the Home Page of MLTD's. WEB Page as a symbol of two related Societies, as a major sister of MLTD.

    Lately, the relations have deepened into a close collaboration to hold joint Educational Courses in Mediterranean Countries( where MLTD's congresses have not yet been organised ), thanks to the coordination of Prof. Uri Seligsohn, MLTD's Councillor and ISTH Education Committee Head.

    The first Joint Educational Course on VENOUS AND ARTERIAL THROMBOSIS was held in Casablanca in May 2004, organised by the MLTD Educational Board President, Prof. S. Coccheri, and financed by ISTH and MLTD.

    The second Educational Course on Thrombosis, being held now in Tunis, in May 2007, is again a joint effort of the MLTD and ISTH with the Collaboration of your active National Tunisian Society of Thrombosis and Haemostasis (ATHETH) under the Patronage of the Ministries of Health of the Republics of Tunisia and Italy.

    In October 2005, a Euro-Argentinean Course on Thrombosis and Antithrombotic Therapies in Cardiovascular Disease, was held in Buenos Aires, (Argentina) organised and supported by the University of Bologna , (Italy) under the Auspices of ISTH with a small financial help and collaboration from MLTD.

    A minute of each Educational Course is handed to the ISTH Educational Committee Head with the summary of the conferences and of the conclusions obtained, together with the evaluation given by the participants and attendants to the Course.

    MLTD's Future

    In June 2008, MLTD will undertake its XX ITC in Athens with a scientific programme including recent hot topics, whose final programme will be decided this July in Geneva at the MLTD's Councillors Meeting on occasion of the XXI ISTH's International Congress on Haemostasis and Thrombosis. The main relevant aspect of this ITC will be multidisciplinary as the President organising the Congress, Prof. Christos Liapis, is a renowned angiologists in Greece and internationally as President of the European Society of Angiology. The following Congress will be organised in Milan, in 2010, by Prof. P.M. Mannucci, internationally reknown Haematologist.

    There is one other task to be undertaken: Nets of Working Teams, which will be the basic working axis of MLTD Society with the collaboration of MLTD Members from the Mediterranean and other international experts to establish Thrombosis epidemiology, diagnosis and treatment in international studies with an evaluation by clinical follow up of patients and by bringing up the newest methods for biological evaluation of patients with both venous Thromboembolism and arterial thrombosis.

    Development of an Homologated MLTD's Page Web, as a means of communication, diffusion and exchange of knowledge between leaders and members of MLTD. Web's homologation has been certified by the Official College of Physicians of Barcelona this 10th of May, 2007.

    MLTD's projects are:

  • - to attract renowned experts and leaders from National Thrombosis Societies from the Mediterranean Countries and to encourage them to participate in MLTD's objectives as Members of the Society.

  • - to participate more actively in the Official Journal of the MLTD, Pathophysiology of Haemostasis and Thrombosis (PHT). All active members have now free access to the current journal 2006-2007 issues.
  • There is a proposal to submit papers to PHT in the original language of each Country ( Arab, Spanish, Greek etc..) for a first evaluation of whether they are worth being published or not, before being finally translated into English for its publication in PHT.

    An important goal is the full integration of all Mediterranean Countries as I mentioned before. These Countries have got an enormous human and scientific potential.

    In this 40th anniversary of MLTD's birth, which will be celebrated in Athens during MLTD's XX ITC, we expect to offer the official creation of a MLTD FOUNDATION, whose full activities will be developed in all the Mediterranean Countries, following the unanimous agreement granted at the Councillors and General Assembly Meetings held last June 2006, in Tel Aviv.

    The objectives and aims of the MLTD FOUNDATION, its Name, Management and Bye-Laws, will be the same ones as those of the MLTD Society. We are hoping that this MLTD FOUNDATION will attract necessary financial funds from Public and Private Institutions interested in the developing of the Mediterranean:

  • - To integrate all Mediterranean Countries, not yet incorporated, into the MLTD.
  • - To create Prizes to highlight projects in clinical and basic research in Thrombosis
  • - To establish Grants for young researchers in Thrombosis interested in participating in MLTD's International Thrombosis Congresses
  • - To create Prizes to promote integration of MLTD's Members in the Net of Working Teams
  • - To promote more Educational Courses in all countries that are not yet integrated into MLTD Society, giving then facilities to register as Members of MLTD
  • - To publish a collaborative "Manual of Validated New Methods in Vascular Biology, Haemostasis and Thrombosis"
  • Last but not least, the future of MLTD is you yourselves, young researchers and multidisciplinary clinicians interested in fighting against Thromboembolic diseases.

    (Conference given in the II Educational Course, held in Tunis, May 18-19th, 2007)

    PRIMER SYMPOSIUM FRANCO-ESPAÑOL SOBRE DIAGN´STICO Y TRATAMIENTO DE LAS ENFERMEDADES TROMBOEMBÓLICAS Y HEMORRÁGICAS

    ACUERDOS DE LA ASAMBLEA FRANCO-ESPAÑOLA

  • PRIMERO: Celebrar una próxima reunión, dentro de dos años, sobre estos temas. El profesor Leroux se pondrá en contacto con colegas italianos, a fin de que el próximo Symposium abarque a varios pueblos latinos.

  • SEGUNDO: Unificar criterios en Francia y España sobre diagnóstico y control de tratamiento clínico y biológico de estas enfermedades, que son la primera causa de muerte en todos los paises civilizados. Por parte de España están de momento de acuerdo en realizar investigaciones conjuntas, y prevención de estas enfermedades, centros especializados de las siguientes provincias: Barcelona, Burgos, Córdoba, Madrid, Sevilla, Vizcaya y las provincias que se vayan sumando a los criterios que hemos establecido en trabajos de próxima publicación, de acuerdo con las conversaciones matenidas con colegas franceses y normas internacionales.
    Los resultados estadísticos de estas profilaxis serán presentadas a nuestras autoridades sanitarias.

  • TERCERO: Expresar todos los participantes de este Primer Symposium Franco-Español, nuestro agradecimiento al Excmo. Sr. Jefe Provincial de Sanidad de Vizcaya, doctor Natalio Sánchez Plaza y al Excmo. Sr. Director General de Sanidad que ha dado su consentimiento a esta Reunión, presentándole los resultados y los fervientes deseos de esta Asamblea Hispano-Francesa arriba expuestos.
  • The Foundation

    The EMLTD Foundation has borned with the aim to achieve cooperation to human, social and health development in promoting the knowledge and practice in the prevention and treatment of atherothromobosis and arterial and venous thromboembolic diseases, the primary cause of death in the world, and mainly to generate new scientific knowledge in these fields fostering scientific research and dissemination thereof cooperating, as well, with the common aims of the EMLTD.

    For more information related to EMLTD Foundation activities, please click here

    Calendar
    24 October 2017
    M T W T F S S
    * * * * * * 1
    2 3 4 5 6 7 8
    9 10 11 12 13 14 15
    16 17 18 19 20 21 22
    23 24 25 26 27 28 29
    30 31 * * * * *
    Associated Societies
       
    SETH SETH
       
    SISET Hemostas
       
    SETH